Please use this identifier to cite or link to this item:
http://hdl.handle.net/11434/1053
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Murphy, Declan | - |
dc.contributor.other | Risbridger, Gail | - |
dc.contributor.other | Bristow, Robert | - |
dc.contributor.other | Sandhu, Shahneen | - |
dc.date | 2017-01 | - |
dc.date.accessioned | 2017-05-03T01:56:05Z | - |
dc.date.available | 2017-05-03T01:56:05Z | - |
dc.date.issued | 2017-05 | - |
dc.identifier.citation | Eur Urol. 2017 May;71(5):748-749 | en_US |
dc.identifier.issn | 0302-2838 | en_US |
dc.identifier.uri | http://hdl.handle.net/11434/1053 | - |
dc.description.abstract | Editorial refers to: Rong Na, S. Lilly Zheng, Misop Han, Hongjie Yu, Deke Jiang, Sameep Shah, Charles M. Ewing, Liti Zhang, Kristian Novakovic, Jacqueline Petkewicz, Kamalakar Gulukota, Donald L. Helseth Jr, Margo Quinn, Elizabeth Humphries, Kathleen E. Wiley, Sarah D. Isaacs, Yishuo Wu, Xu Liu, Ning Zhang, Chi-Hsiung Wang, Janardan Khandekar, et al. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. European Urology, Volume 71, Issue 5, May 2017, Pages 740-747. | en_US |
dc.publisher | Elsevier | en_US |
dc.subject | Prostate Cancer | en_US |
dc.subject | Molecular Differention | en_US |
dc.subject | Indolent Cancer | en_US |
dc.subject | Agressive Cancer | en_US |
dc.subject | Clinicopathologic | en_US |
dc.subject | Prostate-Specific Antigen | en_US |
dc.subject | PSA | en_US |
dc.subject | Repair Gene Defects | en_US |
dc.subject | Triage Patients | en_US |
dc.subject | Lethal Prostate Cancer | en_US |
dc.subject | Urology | en_US |
dc.subject | Australian Prostate Cancer Research Centre Epworth HealthCare, Victoria, Australia | en_US |
dc.subject | UroRenal, Vascular Clinical Institute, Epworth HealthCare, Victoria, Australia | en_US |
dc.title | The Evolving Narrative of DNA Repair Gene Defects: Distinguishing Indolent from Lethal Prostate Cancer. | en_US |
dc.type | Letter | en_US |
dc.rights.holder | Elsevier | en_US |
dc.identifier.doi | 10.1016/j.eururo.2017.01.025 | en_US |
dc.identifier.journaltitle | European Urology | en_US |
dc.description.pubmeduri | https://www.ncbi.nlm.nih.gov/pubmed/28131466 | en_US |
dc.description.affiliates | Division of Cancer Surgery, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia. | en_US |
dc.description.affiliates | The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia. | en_US |
dc.description.affiliates | Prostate Cancer Research Program, Cancer Research Division, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia. | en_US |
dc.description.affiliates | Monash Partners Comprehensive Cancer Consortium and Cancer Program Biomedicine Discovery Institute, Department of Anatomy and Developmental Biology, Monash University, Melbourne, Australia. | en_US |
dc.description.affiliates | Princess Margaret Cancer Centre/University Health Network, Toronto, Canada; Departments of Radiation Oncology and Medical Biophysics, University of Toronto, Toronto, Canada. | en_US |
dc.description.affiliates | Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia. | en_US |
dc.type.studyortrial | Review | en_US |
dc.type.contenttype | Text | en_US |
Appears in Collections: | Cancer Services Epworth Prostate Centre UroRenal, Vascular |
Files in This Item:
There are no files associated with this item.
Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.